Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 6/2018

01-12-2018 | LUNG CANCER

Advances in Imaging and Automated Quantification of Malignant Pulmonary Diseases: A State-of-the-Art Review

Authors: Bruno Hochhegger, Matheus Zanon, Stephan Altmayer, Gabriel S. Pacini, Fernanda Balbinot, Martina Z. Francisco, Ruhana Dalla Costa, Guilherme Watte, Marcel Koenigkam Santos, Marcelo C. Barros, Diana Penha, Klaus Irion, Edson Marchiori

Published in: Lung | Issue 6/2018

Login to get access

Abstract

Quantitative imaging in lung cancer is a rapidly evolving modality in radiology that is changing clinical practice from a qualitative analysis of imaging features to a more dynamic, spatial, and phenotypical characterization of suspected lesions. Some quantitative parameters, such as the use of 18F-FDG PET/CT-derived standard uptake values (SUV), have already been incorporated into current practice as it provides important information for diagnosis, staging, and treatment response of patients with lung cancer. A growing body of evidence is emerging to support the use of quantitative parameters from other modalities. CT-derived volumetric assessment, CT and MRI lung perfusion scans, and diffusion-weighted MRI are some of the examples. Software-assisted technologies are the future of quantitative analyses in order to decrease intra- and inter-observer variability. In the era of “big data”, widespread incorporation of radiomics (extracting quantitative information from medical images by converting them into minable high-dimensional data) will allow medical imaging to surpass its current status quo and provide more accurate histological correlations and prognostic value in lung cancer. This is a comprehensive review of some of the quantitative image methods and computer-aided systems to the diagnosis and follow-up of patients with lung cancer.
Literature
1.
McMahon PM, Kong CY, Johnson BE et al (2008) Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology 248:278–287CrossRef
2.
Harders SW, Balyasnikowa S, Fischer BM (2014) Functional imaging in lung cancer. Clin Physiol Funct Imaging 34:340–355CrossRef
3.
Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605–644CrossRef
4.
Yankeelov TE, Mankoff DA, Schwartz LH et al (2016) Quantitative imaging in cancer clinical trials. Clin Cancer Res: Off J Am Assoc Cancer Res 22(2):284–290CrossRef
5.
UyBico SJ, Wu CC, Suh RD et al (2010) Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30:1163–1181CrossRef
6.
Halpern BS, Schiepers C, Weber WA et al (2005) Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128:2289–2297CrossRef
7.
Henzler T, Schmid-Bindert G, Schoenberg SO et al (2010) Diffusion and perfusion MRI of the lung and mediastinum. Eur J Radiol 76:329–336CrossRef
8.
Matoba M, Tonami H, Kondou T et al (2007) Lung carcinoma: diffusion-weighted MR imaging—preliminary evaluation with apparent diffusion coefficient. Radiology 243:570–577CrossRef
9.
García-Figueiras R, Goh VJ, Padhani AR et al (2013) CT perfusion in oncologic imaging: a useful tool? Am J Roentgenol 200:8–19CrossRef
10.
Horeweg N, van Rosmalen J, Heuvelmans MA et al (2014) Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol 15:1332–1341CrossRef
11.
MacMahon H, Naidich DP, Goo JM et al (2017) Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 284(1):228–243CrossRef
12.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef
13.
Galizia M, Töre H, Chalian H et al (2011) Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis. Acad Radiol 14:1555–1560CrossRef
14.
Marten K, Auer F, Schmidt S et al (2007) Automated CT volumetry of pulmonary metastases: the effect of a reduced growth threshold and target lesion number on the reliability of therapy response assessment using RECIST criteria. Eur Radiol 17:2561–2571CrossRef
15.
Vogel M, Schmücker S, Maksimovic O et al (2012) Reduction in growth threshold for pulmonary metastases: an opportunity for volumetry and its impact on treatment decisions. Br J Radiol 85:959–964CrossRef
16.
Dicken V, Bornemann L, Moltz JH et al (2015) Comparison of volumetric and linear serial CT assessments of lung metastases in renal cell carcinoma patients in a clinical phase IIB study. Acad Radiol 22:619–625CrossRef
17.
Bankier AA, MacMahon H, Goo JM et al (2017) Recommendations for measuring pulmonary nodules at CT: a statement from the Fleischner Society. Radiology 285:584–600CrossRef
18.
Yousaf-Khan U, van der Aalst C, de Jong PA et al (2017) Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax 72(1):48–56CrossRef
19.
de Hoop B, Gietema H, van Ginneken B et al (2009) A comparison of six software packages for evaluation of solid lung nodules using semiautomated volumetry: what is the minimum increase in size to detect growth in repeated CT examinations. Eur Radiol 19:800–808CrossRef
20.
Zhao YR, van Ooijen PM, Dorrius MD et al (2014) Comparison of three software systems for semi-automatic volumetry of pulmonary nodules on baseline and follow-up CT examinations. Acta Radiol 55:691–698CrossRef
21.
Kuhnert G, Boellaard R, Sterzer S et al (2016) Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. Eur J Nucl Med Mol Imaging 43:249–258CrossRef
22.
Boellaard R, Delgado-Bolten R, Oyen WJG et al (2015) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354CrossRef
23.
Markovina S, Duan F, Snyder BS et al (2015) Regional lymph node uptake of [(18)F]fluorodeoxyglucose after definitive chemoradiation therapy predicts local-regional failure of locally advanced non-small cell lung cancer: results of ACRIN 6668/RTOG 0235. Int J Radiat Oncol Biol Phys 93:597–605CrossRef
24.
Paesmans M, Garcia C, Wong CO et al (2015) Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. Eur Respir J 46:1751–1761CrossRef
25.
Cerfolio RJ, Bryant AS, Ohja B et al (2005) The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130:151–159CrossRef
26.
Nahmias C, Hanna WT, Wahl LM et al (2007) Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 48:744–751CrossRef
27.
Gupta NC, Tamim WJ, Graeber GG et al (2001) Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 120:521–527CrossRef
28.
Roberts PF, Follette DM, von Haag D et al (2000) Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 70:1154–1159CrossRef
29.
Nakayama M, Okizaki A, Ishitoya S et al (2013) Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions. Ann Nucl Med 27:163–169CrossRef
30.
Kumar R, Loving VA, Chauhan A et al (2005) Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 46:1819–1824PubMed
31.
Sathekge MM, Maes A, Pottel H et al (2010) Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J 100:598–601CrossRef
32.
Kaneko K, Sadashima E, Irie K et al (2013) Assessment of FDG retention differences between the FDG-avid benign pulmonary lesion and primary lung cancer using dual-time-point FDG-PET imaging. Ann Nucl Med 27:392–399CrossRef
33.
Saleh Farghaly HR, Mohamed Sayed MH, Nasr HA et al (2015) Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work? Indian J Nucl Med 30:314–319CrossRef
34.
Wong CS, Gong N, Chu YC et al (2012) Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. Eur J Radiol 81:2122–2126CrossRef
35.
Usaro A, Ruokonen E, Takala J (1995) Estimation of splanchnic blood flow by the Fick principle in man and problems in the use of indocyanine green. Cardiovasc Res 30:106–112CrossRef
36.
Bevilacqua A, Barone D, Malavasi S et al (2014) Quantitative assessment of effects of motion compensation for liver and lung tumors in CT perfusion. Acad Radiol 21:1416–1426CrossRef
37.
Li Y, Yang ZG, Chen TW et al (2008) Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 61:44–53CrossRef
38.
Ma SH, Le HB, Jia BH et al (2008) Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 8:186CrossRef
39.
Ma S-H, Le H-B, Jia B et al (2008) Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 8:186CrossRef
40.
Wang J, Wu N, Cham MD et al (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193:1090–1096CrossRef
41.
Huellner MW, Collen TD, Gut P et al (2014) Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT. EJNMMI Res 4:6CrossRef
42.
Mirsadraee S, van Beek EJR (2015) Functional imaging: computed tomography and MRI. Clin Chest Med 36:349–363CrossRef
43.
O’Connor JP, Tofts PS, Miles KA et al (2011) Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiol 84:S112–S120CrossRef
44.
Petralia G, Preda L, D’Andrea G et al (2010) CT perfusion in solid-body tumours. Part I: technical issues. Radiol Med 115:843–857CrossRef
45.
Li Y, Yang Z-G, Chen T-W, Yu J-Q, Sun J-Y, Chen H-J (2010) First-pass perfusion imaging of solitary pulmonary nodules with 64-detector row CT: comparison of perfusion parameters of malignant and benign lesions. Br J Radiol 83(993):785–790CrossRef
46.
Yuan X, Zhang J, Quan C et al (2013) Differentiation of malignant and benign pulmonary nodules with first-pass dual-input perfusion CT. Eur Radiol 23(9):2469–2474CrossRef
47.
Ohno Y, Koyama H, Matsumoto K et al (2011) Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT. Radiology 258(2):599–609CrossRef
48.
Jiang B, Liu H, Zhou D (2016) Diagnostic and clinical utility of dynamic contrast-enhanced MR imaging in indeterminate pulmonary nodules: a metaanalysis. Clin Imaging 40:1219–1225CrossRef
49.
Cheng JC, Yuan A, Chen JH et al (2013) Early detection of Lewis lung carcinoma tumor control by irradiation using diffusion-weighted and dynamic contrast-enhanced MRI. PLoS ONE 8:e62762CrossRef
50.
Koenigkam-Santos M, Optazaite E, Sommer G et al (2015) Contrast-enhanced magnetic resonance imaging of pulmonary lesions: description of a technique aiming clinical practice. Eur J Radiol 84:185–192CrossRef
51.
Schaefer JF, Vollmar J, Schick F et al (2004) Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging–perfusion differences in malignant and benign lesions. Radiology 232:544–553CrossRef
52.
Bell LC, Wang K, Munoz Del Rio A et al (2015) Comparison of models and contrast agents for improved signal and signal linearity in dynamic contrast-enhanced pulmonary magnetic resonance imaging. Invest Radiol 50:174–178CrossRef
53.
Ohba Y, Nomori H, Mori T et al (2009) Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg 138:439–445CrossRef
54.
Li B, Li Q, Chen C et al (2014) A systematic review and meta-analysis of the accuracy of diffusion-weighted MRI in the detection of malignant pulmonary nodules and masses. Acad Radiol 21:21–29CrossRef
55.
Wu LM, Xu JR, Hua J et al (2013) Can diffusion-weighted imaging be used as a reliable sequence in the detection of malignant pulmonary nodules and masses? Magn Reson Imaging 31:235–246CrossRef
56.
Usuda K, Zhao XT, Sagawa M et al (2011) Diffusion-weighted imaging is superior to positron emission tomography in the detection and nodal assessment of lung cancers. Ann Thorac Surg 91:1689–1695CrossRef
57.
Regier M, Derlin T, Schwarz D et al (2012) Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)? Eur J Radiol 81:2913–2918CrossRef
58.
Pauls S, Schmidt SA, Juchems MS et al (2012) Diffusion-weighted MR imaging in comparison to integrated [18F]-FDG PET/CT for N-staging in patients with lung cancer. Eur J Radiol 81:178–182CrossRef
59.
Henz-Concatto N, Watte G, Marchiori E et al (2016) Magnetic resonance imaging of pulmonary nodules: accuracy in a granulomatous disease-endemic region. Eur Radiol 26:2915–2920CrossRef
60.
Hochhegger B, Marchiori E, dos Reis DQ et al (2012) Chemical-shift MRI of pulmonary hamartomas: initial experience using a modified technique to assess nodule fat. AJR Am J Roentgenol 199:W331–W334CrossRef
61.
Gillies R, Kinahan P, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577CrossRef
62.
Doi K (2007) Computer-aided diagnosis in medical imaging: historical review, current status and future potential. Comput Med Imaging Graph 31:198–211CrossRef
63.
Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:400665
64.
Ganeshan B, Panayiotou E, Burnand K et al (2012) Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 22:796–802CrossRef
65.
Fried DV, Tucker SL, Zhou S et al (2014) Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 90:834–842CrossRef
66.
Yoon HJ, Sohn I, Cho JH et al (2015) Decoding tumor phenotypes for ALK, ROS1, and RET fusions in lung adenocarcinoma using a radiomics approach. Medicine (Baltimore) 94:e1753CrossRef
67.
Ferreira-Junior JR, Koenigkam-Santos M, Cipriano FEG et al (2018) Radiomics-based features for pattern recognition of lung cancer histopathology and metastases. Comput Methods Programs Biomed 159:23–30CrossRef
68.
Yang J, Zhang L, Fave X (2016) Uncertainty analysis of quantitative imaging features extracted from contrast-enhanced CT in lung tumors. Comput Med Imaging Graph 48:1–8CrossRef
69.
Guo Z, Shu Y, Zhou H et al (2015) Radiogenomics helps to achieve personalized therapy by evaluating patient responses to radiation treatment. Carcinogenesis 36:307–317CrossRef
70.
Rizzo S, Petrella F, Buscarino V et al (2016) CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 26:32–42CrossRef
71.
Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272:568–576CrossRef
Metadata
Title
Advances in Imaging and Automated Quantification of Malignant Pulmonary Diseases: A State-of-the-Art Review
Authors
Bruno Hochhegger
Matheus Zanon
Stephan Altmayer
Gabriel S. Pacini
Fernanda Balbinot
Martina Z. Francisco
Ruhana Dalla Costa
Guilherme Watte
Marcel Koenigkam Santos
Marcelo C. Barros
Diana Penha
Klaus Irion
Edson Marchiori
Publication date
01-12-2018
Publisher
Springer US
Published in
Lung / Issue 6/2018
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-018-0156-0

Other articles of this Issue 6/2018

Lung 6/2018 Go to the issue

ASTHMA

Annexin A5 Protein as a Potential Biomarker for the Diagnosis of Asthma

ASTHMA

Beta 2 Adrenergic Receptor Genetic Polymorphisms in Bronchial Asthma: Relationship to Disease Risk, Severity, and Treatment Response

BRONCHOSCOPY

The Diagnostic Yield, Safety, and Impact of Flexible Bronchoscopy in Non-HIV Immunocompromised Critically Ill Patients in the Intensive Care Unit

ACUTE LUNG INJURY

TIMP-1 Promotes the Immune Response in Influenza-Induced Acute Lung Injury

INTERSTITIAL LUNG DISEASE

Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity

COPD

Imaging Features of Chronic Bronchitis with Preserved Ratio and Impaired Spirometry (PRISm)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits